{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:29:09Z","timestamp":1787905749122,"version":"build-2784847793"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.urolonc.2020.08.002","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T09:28:55Z","timestamp":1600421335000},"page":"234.e9-234.e13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel treatment of upper tract urothelial carcinoma in situ with docetaxel in BCG refractory patients"],"prefix":"10.1016","volume":"39","author":[{"given":"Andrew B.","family":"Katims","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew W.","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Zampini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Mehrazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mantu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.urolonc.2020.08.002_bib0001","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","article-title":"Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review","volume":"110","author":"Cutress","year":"2012","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.002_bib0002","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.urology.2008.06.026","article-title":"A 20-year experience with percutaneous resection of upper tract transitional carcinoma: is there an oncologic benefit with adjuvant Bacillus Calmette Gu\u00e9rin therapy?","volume":"73","author":"Rastinehad","year":"2009","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.002_bib0003","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1080\/17512433.2018.1461560","article-title":"Intracavitary therapies for upper tract urothelial carcinoma","volume":"11","author":"Knoedler","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.08.002_bib0004","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00345-009-0377-1","article-title":"The novel use of intravesical docetaxel for the treatment of non-muscle invasive bladder cancer refractory to BCG therapy: a single institution experience","volume":"27","author":"Barlow","year":"2009","journal-title":"World J Urol"},{"issue":"3","key":"10.1016\/j.urolonc.2020.08.002_bib0005","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.juro.2012.10.068","article-title":"Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin therapy","volume":"189","author":"Barlow","year":"2013","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2020.08.002_bib0006","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3233\/BLC-150008","article-title":"Sequential intravesical gemcitabine and docetaxel for the salvage treatment of non-muscle invasive bladder cancer","volume":"1","author":"Steinberg","year":"2015","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.002_bib0007","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3233\/BLC-170126","article-title":"Oncological outcomes of sequential intravesical gemcitabine and docetaxel in patients with non-muscle invasive bladder cancer","volume":"3","author":"Milbar","year":"2017","journal-title":"Bladder Cancer"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.002_bib0008","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.002_bib0009","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.urology.2013.08.048","article-title":"Comparison of 3 upper tract anticarcinogenic agent delivery techniques in an ex vivo porcine model","volume":"82","author":"Pollard","year":"2013","journal-title":"Urology"},{"issue":"7","key":"10.1016\/j.urolonc.2020.08.002_bib0010","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1002\/cncr.24147","article-title":"Surveillance of urothelial carcinoma","volume":"115","author":"David","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.002_bib0011","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.eururo.2015.06.044","article-title":"European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2020 update","volume":"68","author":"Roupr\u00eat","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2020.08.002_bib0012","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0022-5347(05)67019-X","article-title":"Upper tract urothelial neoplasms: incidence and survival during the last 2 decades","volume":"164","author":"Munoz","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2020.08.002_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/hdi.12165","article-title":"Survival and other clinical outcomes of maintenance hemodialysis patients in Taiwan: a 5-year multicenter follow-up study","author":"Chen","year":"2014","journal-title":"Hemodial Int"},{"issue":"4","key":"10.1016\/j.urolonc.2020.08.002_bib0014","first-page":"799","article-title":"One-year mortality after dialysis initiation among older adults","volume":"18","author":"Wachterman","year":"2019","journal-title":"JAMA Int Med"},{"issue":"7","key":"10.1016\/j.urolonc.2020.08.002_bib0015","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.urolonc.2019.02.004","article-title":"Endocavitary treatment for upper tract urothelial carcinoma: a meta-analysis of the current literature","volume":"37","author":"Foerster","year":"2019","journal-title":"Urol Oncol"},{"issue":"12","key":"10.1016\/j.urolonc.2020.08.002_bib0016","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00345-018-2349-9","article-title":"Salvage topical therapy for upper tract urothelial carcinoma","volume":"36","author":"Balasubramanian","year":"2018","journal-title":"World J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2020.08.002_bib0017","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1590\/s1677-5538.ibju.2016.0258","article-title":"Which is best method for instillation of topical therapy to the upper urinary tract? An in vivo porcine study to evaluate three delivery methods","volume":"43","author":"Liu","year":"2017","journal-title":"Int Braz J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303677?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143920303677?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:41Z","timestamp":1761041981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143920303677"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1078143920303677"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.002","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel treatment of upper tract urothelial carcinoma in situ with docetaxel in BCG refractory patients","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2020.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}